Fungal growth inhibitory properties of new phytosphingolipid analogues by Mormeneo, David et al.
ORIGINAL ARTICLE
Fungal growth inhibitory properties of new
phytosphingolipid analogues
D. Mormeneo1,2, A. Manresa3, J. Casas2, A. Llebaria2 and A. Delgado1,2
1 Facultat de Farma`cia, Universitat de Barcelona, Unitat de Quı´mica Farmace`utica (Unitat Associada al CSIC), Barcelona, Spain
2 Research Unit on Bioactive Molecules (RUBAM), Institut d’Investigacions Quı´miques i Ambientals de Barcelona (IIQAB-CSIC), Barcelona, Spain
3 Departament de Microbiologia i Parasitologı´a Sanita`ries, Facultat de Farma`cia, Universitat de Barcelona, Barcelona, Spain
Introduction
Sphingolipids (SLs) are ubiquitous components of cellular
membranes of eukaryotic cells. Until the late 1980s, they
were believed to have a protecting role against harming
environmental factors, forming a mechanically stable and
chemically resistant outer leaflet of the plasma membrane
lipid bilayer comprising a set of different glycolipids also
known as glycocalix (Kolter and Sandhoff 1999). How-
ever, in addition to this structural role, SLs are now
considered as biomolecules with important implications
in cell recognition and signalling processes (Hakomori
1990), cell growth regulation (Chung et al. 2001; Fishman
2002) and other processes related with the pathogenesis
of several diseases (Claus et al. 2000). Over the last years,
much effort has been made in order to better understand
the biosynthesis and regulation of SLs in different species.
In this context, important biosynthetic ⁄metabolic and
structural differences between mammal and fungal SLs
have been observed (Sugimoto et al. 2004), which set the
stage for the development of new and selective antifungal
agents (Thevissen et al. 2005). Thus, the common precur-
sor dihydrosphingosine (DHS, Fig. 1) is hydroxylated in
fungi at C4 position to phytosphingosine (PHS) and fur-
ther acylated or phosphorylated to phytoceramide (PHC)
or PHS-1-phosphate, respectively. In addition, fungal
glycosphingolipids (GSLs) are biosynthesized from inosi-
tolphosphorylceramide (IPC) by means of a specific syn-
thase (IPC synthase), a common enzyme in fungi and
plants (Sugimoto et al. 2004).
In recent years, the number of patients with serious
fungal opportunistic infections has risen dramatically
because of the increased number of immunocompro-
mised patients, either by HIV infection (Ampel 1996;
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Abstract
Aims: To study the growth inhibitory properties of a series of phytosphingo-
sine (PHS) and phytoceramide (PHC) analogues.
Methods and Results: A panel of two yeast (Candida albicans and Saccharomy-
ces cerevisiae) and six moulds (Aspergillus repens, Aspergillus niger, Penicillium
chrysogenum, Cladosporium cladosporioides, Arthroderma uncinatum and Penicil-
lium funiculosum) has been used in this study. A series of new PHS and PHC
analogues differing at the sphingoid backbone and the functional group at C1
position were synthesized.
Conclusions: Among PHS analogues, 1-azido derivative 1c, bearing the natural
d-ribo stereochemistry, showed a promising growth inhibitory profile. Among
PHC analogues, compound 12, with a bulky N-pivaloyl group and a Z double
bond at C3 position of the sphingoid chain, was the most active growth
inhibitor. Minimal inhibitory concentration values were in the range of
23–48 lmol l)1 for 1c and 44–87 lmol l)1 for 12.
Significance and Impact of the Study: Only scattered data on the antifungal
activity of phytosphingolipids have been reported in the literature. This is the
first time that a series of analogues of this kind are tested and compared to dis-
cern their structural requirements for antifungal activity.
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Samaranayake et al. 2002), intense cancer chemotherapy
(Bow 1998; Castagnola et al. 2006) or organ transplant
(Marr and Bowden 1999; Fishman 2002; Brown 2004).
However, the increasing tax of fungal resistance to
standard treatments (Chamilos and Kontoyiannis 2005;
Klepser 2006) has boosted the need of new therapeutic
agents for specific pharmacological targets. Conse-
quently, the use of SL analogues as potential and selec-
tive inhibitors of SL metabolism in fungi is an attractive
approach.
Sphingoid long chain bases have been reported to have
important functional roles in yeast cell signalling and heat
stress responses (Liu et al. 2005b). In addition, DHS and
PHS have been reported as fungicides Aspergillus nidulans
(Cheng et al. 2003) and also as inhibitors of tryptophan
import and yeast cell growth (Skrzypek et al. 1998). This
effect is promoted by stimulation of ubiquitin-dependent
proteolysis of the nutrient permeases (Chung et al. 2000).
Furthermore, some alkaloids containing an alkyl amino
alcohol skeleton, isolated from different marine inverte-
brate species, have also been described as antifungal
agents (Clark et al. 2001; Nicholas et al. 2002; Searle and
Molinski 1993).
In this study, we would like to report on the antifun-
gal properties of a series of phytosphingolipid (PSL)
analogues resulting from the systematic replacement of
the C1–OH group present in natural SLs with an amino
or an azido group. On the other side, all different
stereochemistries at the C3–C4 moiety of the sphingoid
chain have been explored, as well as its replacement
with a Z or E double bond. Finally, PHC analogues aris-
ing from acylation of the corresponding sphingoid bases
with a bulky pivaloyl residue have been synthesized and
tested. The N-pivaloyl group was chosen by analogy
with other SL analogues previously synthesized in our
group (unpublished data). From a structural standpoint,
the new PSL analogues here reported can be viewed as:
(i) PHS analogues (Fig. 2); (ii) PHC analogues (Fig. 3)
and (iii) unsaturated PHS or PHC analogues resulting
from replacement of the C3–C4 dihydroxy moiety with
a double bond (Fig. 4).
Materials and methods
Micro-organisms
The micro-organisms used to evaluate the activity of the
new compounds were yeast of the genera Candida
albicans ATCC 10231 and Saccharomyces cerevisiae ATCC
9763 and the moulds Aspergillus repens IMI 0161144,
Aspergillus niger ATCC 16404, Penicillium chrysogenum
ATCC 9480, Cladosporium cladosporioides ATCC 16022,
Arthroderma uncinatum ATCC 6082 and Penicillium funi-
culosum CECT 2914. Micro-organisms were maintained
frozen at )80C on cryobilles (EAS laboratories, Paypin,
France). Prior to minimal inhibitory concentration (MIC)
analysis, a cryobille of each micro-organism was removed
from the freezer and cultivated on Sabouraud dextrose
agar (ADSA Micro, Barcelona, Spain) at 25C for 72–
96 h and subcultured twice in the same conditions.
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Figure 1 Metabolic routes in mammals and fungi.
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Antimicrobial agents
The compounds tested for antifungal properties were
synthesized as described by Mormeneo et al. (2007).
The antimicrobial solutions were prepared by a serial
twofold dilutions of the product diluted in the assay
medium to get the test concentration (256–
0Æ25 mg l)1). An aliquot of 200 ll was dispensed in
each well.
Minimal inhibitory concentration
The minimal inhibitory concentration was determined
in vitro by using a broth microdilution assay following
the guidelines of the Clinical and Laboratory Standard
(NCCLS) described elsewhere (Espinel-Ingrof et al. 2003;
Woods and Washington 1995). The test was performed
by using sterile disposable 96-well polystyrene microtiter
plate (Nunc, Roskilde, Denmark).
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Figure 3 Phytoceramide analogues tested in this study.
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Figure 4 Unsaturated analogues tested in this study.
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Figure 2 Phytosphingosine analogues tested in this study.
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Preparation of inocula
In the case of yeast, four colonies were picked up from the
Sabouraud dextrose agar media and suspended in sterile
saline to match the turbidity produced by 0Æ5 McFarland
barium sulfate standard. This produces a cell suspension of
about 106 CFC ml)1. In the case of the filamentous fungi,
a saline solution with polysorbate (1% w ⁄ v) of spores har-
vested from Sabouraud dextrose agar medium was counted
in a Pettrof-Hausser chamber (Hauser Scientific, Horsman,
PA) and adjusted by diluting 1 : 100 in Sabouraud dex-
trose broth to 106 spores ml)1; 200 ll of broth media con-
taining the antimicrobial compounds were added to each
well of a microtitre plate using a multichannel pipette.
About 10 ll of inoculum of each micro-organism was
added to provide a final test inocula of about 104 UFC
ml)1. MIC was defined as the lowest concentration of anti-
microbial agent that inhibits the development of visible
growth after 24–96 h of incubation at 30C. Experiments
were conducted in duplicate.
Results
The activities of 1-octadecanol (C18OH), 1-azidoctadecane
(C18N3) and octadecylamine (C18NH2) were determined
to evaluate any unspecific background activity, together
with that of the reference antifungal drug miconazole
(Sud and Feingold 1981). Aliphatic octadecyl alcohol
and azide were inactive (MIC > 474 lmol l)1 and
433 lmol l)1, respectively) in all the antimicrobial assays.
Similarly, octadecylamine showed no significant growth
inhibitory properties against the micro-organisms under
study (Tables 1 and 2).
PHS analogues
1-Amino PHS analogues (1b–4b; Fig. 2), were inactive in
all the assays, with MIC ‡ 404 lmol l)1, a concentration
higher than that required for octadecylamine for growth
inhibition, whereas only 1-azido PHS analogue d-ribo 1c
(Fig. 2) showed a significant activity, with MIC values
ranging from 23 to 48 lmol l)1 in all the micro-organ-
isms tested (Table 1).
Activity of 1-hydroxy PHS diastereomers (1a–4a;
Fig. 2) against yeasts indicated that only l-lyxo 4a was
active against both C. albicans and S. cerevisiae (MIC:
50 lmol l)1), while l-arabino 2a was active against
S. cerevisiae and 1a and 3a were less active against S. cere-
visiae (MIC: 101 lmol l)1)or inactive against C. albicans
(Table 1). Similar growth inhibitory profile was observed
for 1a–4a against A. uncinatum and C. cladosporoides,
Table 1 PHS analogues and unsaturated PHS analogues
Micro-organism
Compound MIC (lmol l)1)
Miconazole C18NH2 1a 2a 3a 4a 1c 2c 3c 4c 9a 10a 9b 10b
Candida albicans 77 >238 >403 >403 >403 50 48 >374 >374 >374 >452 >452 >453 >453
Saccharomyces cervisiae 77 >238 101 50 101 50 23 374 94 187 113 28 >453 >453
Aspergillus repens 0Æ6 238 50 0Æ8 101 50 48 374 187 187 226 113 >453 453
Aspergillus niger 9Æ6 >238 403 >403 >403 >403 48 >374 >374 >374 452 113 >453 >453
Penicillium chrysogenum 2Æ4 n.a. 50 101 1202 50 48 >374 374 >374 226 113 n.a. n.a.
Cladosporium cladosporioides 9Æ6 238 50 25 25 50 23 374 187 187 226 226 227 453
Arthroderma uncinatum 2Æ4 119 50 25 50 25 23 374 187 187 113 56 113 227
Penicillium funiculosum 77 >238 403 50 403 202 48 374 374 374 113 113 >453 >453
n.a., not available, PHS, phytosphingosine, MIC, minimal inhibitory concentration.
Table 2 1-Amino-PHC and unsaturated
1-amino-PHC analogues
Micro-organism
Compound MIC (lmol l)1)
Miconazole C18NH2 5b 6b 7b 8b 11 12
Candida albicans 77 >238 >320 >320 >320 320 349 44
Saccharomyces cervisiae 77 >238 >320 >320 320 160 44 44
Aspergillus repens 0Æ6 238 160 >320 320 320 175 44
Aspergillus niger 9Æ6 >238 80 160 >320 160 175 44
Penicillium chrysogenum 2Æ4 n.a. 160 160 320 160 349 44
Cladosporium cladosporoides 9Æ6 238 160 320 320 320 349 87
Arthroderma uncinatum 2Æ4 119 160 160 320 160 44 44
Penicillium funiculosum 77 >238 320 160 320 160 87 87
n.a., not available; PHS, phytosphingosine, MIC, minimal inhibitory concentration.
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while A. niger was resistant in all cases (Table 1). It is
worth noting the significant activity of l-arabino 2a
against A. repens (MIC: 0Æ8 lmol l)1) and A. uncinatum
or C. cladosporoides (MIC: 25 lmol l)1), compared with
the corresponding diastereomer d-ribo 1a, which pre-
sented a moderate activity against A. repens, P. crisoge-
num, C. cladosporoides and A. uncinatum (MIC: 50 lmol
l)1). Similar growth inhibition properties were found for
4a (Table 1). Higher MIC values were observed for 3a,
with the exception of C. cladosporoides (MIC: 25 lmol
l)1) and A. uncinatum (MIC: 50 lmol l)1).
Concerning unsaturated 1-hydroxy PHS analogues 9a
and 10a (Table 1), the Z isomer 10a was slightly more
active against all the micro-organisms tested in the study.
As the simple aliphatic octadecanol was inactive in the
same microbial panel, it is reasonable to assume that the
activity shown by 10a must be due to specific interactions
with cellular targets. On the other hand, the activities
observed for alcohols 9a and 10a were not paralleled by
those of the unsaturated diamines 9b and 10b (Table 1).
In these cases, MICs were higher than that of simple octa-
decylamine, this suggesting the operation of nonspecific
modes of action.
PHC analogues
The 1-hydroxy (5a–8a) and 1-azido (5c–8c) PHC ana-
logues (Fig. 3) tested in this study were not active as
growth inhibitors against the selected microbial panel,
while some of the 1-amino derivatives 5b–8b (Fig. 3)
were moderately active (Table 2). Unsaturated PHC ana-
logues 11 and 12 (Fig. 4) afforded interesting results. It is
worth noting the good, even though unspecific, growth
inhibitory activity shown by the unsaturated PHC ana-
logue 12 and the lower activity shown by the isomeric E
analogue 11 (Table 2). The influence of N-acylation on
the activity of these unsaturated analogues is also remark-
able. Thus, N-pivaloyl derivatives 11 and 12 were more
active than their corresponding lyso counterparts 9b and
10b (Table 1), respectively. This effect was even more
pronounced on Z isomers, as evidenced by comparison of
the growth inhibition patterns of 10b and 12 (Tables 1
and 2).
Discussion
Design and synthesis of different PSL analogues, based on
the modifications on the C1, C3 and C4 positions, were
carried out as a new strategy on the search of antifungal
compounds with the aim to interfere specifically on bio-
chemical pathways of fungal SL biosynthesis. The above
results (summarized in Fig. 5) show that the growth
inhibitory properties of the tested analogues depend on a
delicate balance between the functionality at C1 and C3–
C4 positions, as well as N-acylation of the sphingoid
chain. In some instances, the combination of two of the
above requirements is essential to improve the activity, as
in 1-amino-N-pivaloyl PHC analogues. To the best of our
knowledge, no systematic studies of the antifungal activity
of a series of PHC analogues have been reported so far
and only a short chain ceramide (C2-Cer) analogue has
been tested in S. cerevisiae (Fishbein et al. 1993).
Concerning PHS analogues, it has been reported that
C. albicans growth was inhibited by natural d-ribo PHS
(1a) at concentrations between 152 and 269 lg ml)1
(Nenoff and Haustein 2002), whereas different values
have been found for S. cerevisiae, depending on the strain
used. In this case, both natural d-ribo PHS (1a) and
diastereomers 2a–4a (Fig. 2) showed growth inhibitory
properties, although with different selectivities and con-
centration ranks. It is accepted that effective incorpora-
tion of PHS into PSLs requires both phosphorylation and
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Figure 5 Activity of phytosphingolipid
analogues tested in this study. The Z axis is
expressed as llmol)1, the reciprocal of the
minimal inhibitory concentration. *Value: 1Æ25
(0Æ8 lmol l)1). ( ), C. albicans; ( ), S. cerevi-
siae; ( ), A. repense; ( ); A. niger; ( ), P. ch-
rysogenum; ( ), C. cladosporides; ( ), A.
uncinatum; , P. funiculosum.
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subsequent dephosphorylation. These reactions serve to
properly localize the sphingoid base and to allow for effi-
cient action of downstream enzymes, because yeast with
deleted phosphatase gene (LCB3) are more resistant to
PHS treatment (Brace et al. 2007). Although additional
experiments are required along this line, targets of natural
PHS, such as AGC-type protein kinases (Liu et al. 2005a)
and ⁄or nutrient permeases (Chung et al. 2000), seem rea-
sonable candidate targets for the above PHS analogues.
Replacement of the 1-hydroxy functionality with an azide
group was deleterious, except for the d-ribo isomer 1c,
one of the most potent analogues found in this study
(Table 1). Azide 1c, but not its diastereomers at C3–C4
positions, is a growth inhibitor of all the organisms tested
at low lM concentration (Table 1 and Fig. 5). This stere-
oselectivity suggests the operation of specific interactions
with yet undisclosed cellular targets.
Interestingly, simple unsaturated amino alcohols 9a
and 10a behaved as modest fungal growth inhibitors of
several of the tested species, specially the Z isomer 10a
(Table 1 and Fig. 5). Activity was lost in 1-amino ana-
logues 9b and 10b (Table 1) but notably increased in 1-
amino-N-pivaloyl analogues, in particular the Z isomer
12, a good growth inhibitor of the entire microbial panel
(Table 2 and Fig. 5). On the other hand, the correspond-
ing E isomer 11 showed a higher selectivity, because it
was as active as 12 against only three of the eight organ-
isms tested in this study.
In conclusion, compounds 1c and 12 have been discov-
ered as two new PSL analogues with promising antifungal
growth inhibitory properties. Further studies are currently
underway to disclose its mode and ⁄or mechanism of
action, as well as their roles as modulators of SL biosyn-
thesis.
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